1 Introduction to Research & Analysis Reports
1.1 Targeted Therapy for Bladder Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Therapy for Bladder Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Therapy for Bladder Cancer Overall Market Size
2.1 Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2029
2.2 Global Targeted Therapy for Bladder Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Therapy for Bladder Cancer Players in Global Market
3.2 Top Global Targeted Therapy for Bladder Cancer Companies Ranked by Revenue
3.3 Global Targeted Therapy for Bladder Cancer Revenue by Companies
3.4 Top 3 and Top 5 Targeted Therapy for Bladder Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Therapy for Bladder Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Players in Global Market
3.6.1 List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Targeted Therapy for Bladder Cancer Market Size Markets, 2022 & 2029
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
4.2.1 By Type – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
4.2.2 By Type – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
4.2.3 By Type – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
5.2.1 By Application – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
5.2.2 By Application – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
5.2.3 By Application – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2029
6.2 By Region – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
6.2.1 By Region – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
6.2.2 By Region – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
6.2.3 By Region – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.3.2 US Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.3.3 Canada Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.3.4 Mexico Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.4.2 Germany Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.3 France Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.4 U.K. Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.5 Italy Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.6 Russia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.8 Benelux Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.5.2 China Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.3 Japan Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.4 South Korea Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.6 India Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.6.2 Brazil Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.6.3 Argentina Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.7.2 Turkey Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.3 Israel Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.5 UAE Targeted Therapy for Bladder Cancer Market Size, 2018-2029
7 Targeted Therapy for Bladder Cancer Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Targeted Therapy for Bladder Cancer Major Product Offerings
7.1.4 Pfizer Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Company Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Targeted Therapy for Bladder Cancer Major Product Offerings
7.2.4 Merck KGaA Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Targeted Therapy for Bladder Cancer Major Product Offerings
7.3.4 Roche Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 Astellas
7.4.1 Astellas Company Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Targeted Therapy for Bladder Cancer Major Product Offerings
7.4.4 Astellas Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News & Latest Developments
7.5 Janssen Biotech
7.5.1 Janssen Biotech Company Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Targeted Therapy for Bladder Cancer Major Product Offerings
7.5.4 Janssen Biotech Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Major Product Offerings
7.6.4 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Targeted Therapy for Bladder Cancer Major Product Offerings
7.7.4 Merck & Co. Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Targeted Therapy for Bladder Cancer Major Product Offerings
7.8.4 Gilead Sciences Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Targeted Therapy for Bladder Cancer Market Opportunities & Trends in Global Market
Table 2. Targeted Therapy for Bladder Cancer Market Drivers in Global Market
Table 3. Targeted Therapy for Bladder Cancer Market Restraints in Global Market
Table 4. Key Players of Targeted Therapy for Bladder Cancer in Global Market
Table 5. Top Targeted Therapy for Bladder Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Targeted Therapy for Bladder Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Targeted Therapy for Bladder Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Targeted Therapy for Bladder Cancer Product Type
Table 9. List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Targeted Therapy for Bladder Cancer Product Offerings
Table 32. Pfizer Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Merck KGaA Company Summary
Table 35. Merck KGaA Targeted Therapy for Bladder Cancer Product Offerings
Table 36. Merck KGaA Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. Merck KGaA Key News & Latest Developments
Table 38. Roche Company Summary
Table 39. Roche Targeted Therapy for Bladder Cancer Product Offerings
Table 40. Roche Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Key News & Latest Developments
Table 42. Astellas Company Summary
Table 43. Astellas Targeted Therapy for Bladder Cancer Product Offerings
Table 44. Astellas Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Astellas Key News & Latest Developments
Table 46. Janssen Biotech Company Summary
Table 47. Janssen Biotech Targeted Therapy for Bladder Cancer Product Offerings
Table 48. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Janssen Biotech Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Product Offerings
Table 52. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Targeted Therapy for Bladder Cancer Product Offerings
Table 56. Merck & Co. Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Gilead Sciences Company Summary
Table 59. Gilead Sciences Targeted Therapy for Bladder Cancer Product Offerings
Table 60. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Targeted Therapy for Bladder Cancer Segment by Type in 2022
Figure 2. Targeted Therapy for Bladder Cancer Segment by Application in 2022
Figure 3. Global Targeted Therapy for Bladder Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Targeted Therapy for Bladder Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Targeted Therapy for Bladder Cancer Revenue in 2022
Figure 8. By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 16. US Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 28. China Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck KGaA Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astellas Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck & Co. Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
| ※参考情報 膀胱がんは、尿路系の主要な悪性腫瘍の一種であり、特に中高年層に多く見られます。従来の治療法としては、手術、放射線療法、化学療法が一般的に行われてきました。しかし、近年、膀胱がんの治療においては標的療法が注目されています。標的療法は、がん細胞の特定の分子や経路を標的とし、より効果的かつ副作用を抑えた治療を目指すものです。そのため、微細なメカニズムに対する理解が重要となります。 標的療法の定義として、特定のがん細胞の遺伝子変異や異常に着目した治療法とされます。これにより、従来の化学療法よりも、がん細胞に対する選択的な攻撃が可能になります。標的療法は、患者ごとの腫瘍の特徴に基づく個別化されたアプローチを強調しており、これにより治療の効果を最大化し、副作用を最小限に抑えることが期待されています。 膀胱がんにおける標的療法の特徴は、まず、特定の分子標的を持つ薬剤による治療です。がん細胞の表面に存在する受容体や、その内部の細胞シグナル伝達経路を標的とすることで、がん細胞の成長や増殖を抑えることができます。多くの場合、これらの標的は、がんの発生や進行に寄与する増殖因子やその受容体です。例えば、上皮成長因子受容体（EGFR）や、血管内皮増殖因子（VEGF）などが代表的です。これらの分子に対する抗体や、邪魔する経路を選択的に抑制する小分子薬が開発されています。 標的療法の種類としては、モノクローナル抗体療法、キナーゼ阻害剤、免疫チェックポイント阻害剤などがあります。モノクローナル抗体療法は、特定のがん細胞表面の抗原に特異的に結合する抗体を用い、がん細胞の死を促進します。これにより、患者の免疫系ががん細胞を攻撃する手助けとなるのです。一方、キナーゼ阻害剤は、細胞内のシグナル伝達を阻害することで、がん細胞の成長を抑制します。これらの薬剤はいずれも、患者の腫瘍に特異的な遺伝子変異の有無を調べることで、効果が期待できる対象を特定することができます。 用途としては、膀胱がんの進行した状態において特に有用です。従来の治療に耐性を示す場合や、手術が困難な患者に対しても、標的療法は有望な選択肢となります。個別化医療の一環として、遺伝子診断を用いて最適な標的療法を選択することが重要です。これにより、患者への治療効果を高めるだけでなく、不要な副作用のリスクを減少させることができます。 関連技術としては、次世代シーケンシング（NGS）が挙げられます。NGSを用いることで、膀胱がんに関連する遺伝子変異や、特定の生物学的マーカーの存在を迅速に解析することができます。これにより、どの標的薬剤が最も効果が期待できるかを判断する材料を提供します。また、がん免疫療法との併用が研究されており、患者の免疫系を活性化させることで、標的療法の効果をさらに強化できる可能性もあります。 さらに、膀胱がんにおける標的療法の実施には、患者の生存率を改善するための臨床試験が重要な役割を果たしています。新たな治療法の有効性を評価するために、多くの臨床試験が進行中です。これによって、将来的には膀胱がんの標準治療としての地位を確立することが期待されています。 膀胱がんの治療における標的療法は、その個別化されたアプローチによって大きな進展を遂げつつあります。特に、患者一人ひとりの腫瘍の遺伝的背景や生物学的特性を考慮に入れることで、より効果的な治療が可能となります。今後も新たな研究が進むことで、さらなる治療法の開発が期待されます。そして、こうした標的療法が膀胱がん患者の生活の質を向上させ、長期的な生存率を高めることに貢献することが望まれています。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
